What is the survival rate in adult-to-adult living donor liver transplantation with a graft-to-recipient weight ratio of 0.65?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Survival Rate in LDLT with GRWR 0.65

A graft-to-recipient weight ratio (GRWR) of 0.65% in adult-to-adult living donor liver transplantation (LDLT) is below the recommended minimum threshold of 0.8% and carries significantly increased risks, though survival is possible under favorable conditions with careful patient selection.

Guideline-Based Minimum Standards

The EASL Clinical Practice Guidelines explicitly state that the minimum graft size must be at least 0.8% GRWR to ensure viability of both patient and graft 1. This represents the established safety threshold based on European registry data and expert consensus.

Survival Outcomes with GRWR 0.65%

Short-term Survival

When GRWR falls to 0.65%, the data shows:

  • 3-month graft survival drops to approximately 86.8% compared to 98.1% for GRWR ≥0.6% 2
  • 90-day mortality can reach 30% in high-acuity patients with GRWR between 0.65-0.75% 3
  • Early graft loss (within 3 months) occurs in 22.6% of patients with GRWR <0.8% 4

Long-term Survival

  • 5-year overall survival is approximately 50% in high-acuity patients receiving grafts with GRWR 0.65-0.75% 3
  • One study reported 1-year and 3-year graft survival rates of 100% and 91.7% respectively for GRWR <0.7%, but this was in highly selected patients with low MELD scores (mean 16.3) and without portal pressure modulation 5

Critical Risk Factors at GRWR 0.65%

Small-for-Size Syndrome (SFSS)

The incidence of SFSS increases dramatically:

  • 13.0% with GRWR <0.7% versus 0.7% with GRWR ≥0.8% 5
  • SFSS risk is significantly higher across all studies when GRWR drops below 0.7% 4, 2

Other Complications

  • Hepatic artery thrombosis: 8.7% (versus 1.9% with GRWR ≥0.8%) 5
  • Post-transplant kidney injury requiring dialysis: 16.1% (versus 3.2% with GRWR >1.0%) 4
  • Delayed recovery of liver function is more common 4

When GRWR 0.65% May Be Acceptable

The most recent evidence suggests GRWR as low as 0.65-0.7% can be considered only under highly favorable conditions 5, 4:

Required Favorable Conditions:

  • Low MELD score (<20, ideally <16) - This is the single most important factor 5, 2
  • Young donor age - Older donors significantly increase SFSS risk 2
  • Hepatocellular carcinoma as indication (not acute decompensation) 5
  • Low recipient body mass index 5
  • Intraoperative portal venous hemodynamic monitoring with portal inflow modulation capability 4
  • Experienced transplant center with expertise in managing small grafts

Absolute Contraindications for GRWR 0.65%:

  • MELD score ≥30 - Associated with 30% 90-day mortality 3
  • Child-Pugh score ≥11 - Poor outcomes documented 3
  • GRWR <0.65% - The most recent 2025 study identifies this as the critical threshold where risk becomes unacceptable (HR: 16.951 for early graft loss) 4

Clinical Decision Algorithm

For GRWR 0.65%:

  1. If MELD <20, young donor, HCC indication, experienced center → Proceed with intensive intraoperative portal pressure monitoring
  2. If MELD 20-29 → Consider dual graft LDLT or wait for deceased donor
  3. If MELD ≥30 or Child-Pugh ≥11 → Do NOT proceed; pursue alternative options (dual graft LDLT, deceased donor, or consider delisting if too high risk)
  4. If GRWR will be <0.65% → Absolutely contraindicated; pursue alternatives

Important Caveats

The 2016 EASL guidelines predate the more recent research showing that carefully selected patients can tolerate GRWR 0.7-0.8% 5, 4. However, the 2025 data definitively shows GRWR <0.7% remains a significant risk factor for early graft loss even with portal pressure monitoring 4. The guideline threshold of 0.8% remains the safest recommendation for general practice.

GRWR 0.65% should only be attempted in exceptional circumstances at high-volume centers with the specific favorable conditions outlined above. The expected 1-year survival ranges from 58-100% depending entirely on patient selection, with the lower end representing high-acuity patients and the upper end representing ideal candidates 5, 3.

References

2
Research

Outcomes of living donor liver transplant recipients receiving grafts with the graft-to-recipient weight ratio less than 0.6%: A matched pair analysis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2024

Related Questions

What is the minimum recommended duration of antimicrobial therapy for a deep puncture wound?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
Should an asymptomatic urine culture with 10,000–49,000 CFU/mL Escherichia coli be treated?
When should endotracheal intubation be performed in a patient with combined cardiogenic and septic shock from urosepsis, acute kidney injury with severe metabolic acidosis, elevated lactate, markedly reduced creatinine clearance, high urea, tachypnea, and severe acidemia (pH < 7.25) despite low PaCO₂ and normal PaO₂?
What is the valproic acid dose equivalent to levetiracetam 500 mg twice daily?
What medication, dose, and frequency are recommended for severe agitation in a patient receiving levetiracetam (Keppra) 1 g twice daily and phenytoin 300 mg nightly?
What is the detailed rehabilitation protocol for a 65-year-old male with a left clavicular fracture managed non‑operatively?
Can naltrexone benefit co‑occurring psychiatric conditions such as depressive disorder, anxiety disorder, post‑traumatic stress disorder, or borderline personality disorder?
Should risperidone be added, and what is the appropriate dosing schedule for a patient on levetiracetam and phenytoin after acute agitation measures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.